Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - irinotecan hydrochloride trihydrate 20 mg/ml - eq. irinotecan 17,33 mg/ml - concentrate for solution for infusion - 20 mg/ml - irinotecan hydrochloride trihydrate 20 mg/ml - irinotecan

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 500 mg - injection, concentrated - excipient ingredients: sorbitol; lactic acid; sodium hydroxide; water for injections - irinotecan injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 300 mg - injection, concentrated - excipient ingredients: sorbitol; lactic acid; sodium hydroxide; water for injections - irinotecan injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: lactic acid; sorbitol; sodium hydroxide; water for injections - irinotecan injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: water for injections; lactic acid; sodium hydroxide; sorbitol - irinotecan injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Kanada - enska - Health Canada

fresenius kabi canada ltd - irinotecan hydrochloride (irinotecan hydrochloride trihydrate) - solution - 20mg - irinotecan hydrochloride (irinotecan hydrochloride trihydrate) 20mg - antineoplastic agents

Írland - enska - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - oxaliplatin - concentrate for solution for infusion - 5 milligram(s)/millilitre - platinum compounds; oxaliplatin

Bandaríkin - enska - NLM (National Library of Medicine)

fresenius kabi usa, llc - irinotecan hydrochloride (unii: 042laq1iis) (irinotecan - unii:7673326042) - irinotecan hydrochloride 20 mg in 1 ml - - irinotecan hydrochloride injection is indicated as a component of first-line therapy in combination with 5- fluorouracil (5-fu) and leucovorin (lv) for patients with metastatic carcinoma of the colon or rectum. - irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. irinotecan hydrochloride injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients. pregnancy category d [see warnings and precautions (5.9) ] irinotecan hydrochloride injection can cause fetal harm when administered to a pregnant woman. radioactivity related to 14 c-irinotecan crosses the placenta of rats following intravenous administration of 10 mg/kg (which in separate studies produced an irinotecan cmax and auc about 3 and 0.5 times, respectively, the corresponding values in patients administered 125 mg/m2 ). intravenous administration of irinotecan 6

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - irinotecan hydrochloride trihydrate 20 mg/ml - eq. irinotecan 17,33 mg/ml - concentrate for solution for infusion - irinotecan

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - irinotecan hydrochloride trihydrate 20 mg/ml - eq. irinotecan 17,33 mg/ml - concentrate for solution for infusion - irinotecan